<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374021</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002747</org_study_id>
    <nct_id>NCT02374021</nct_id>
  </id_info>
  <brief_title>Treatments Against RA and Effect on FDG-PET/CT</brief_title>
  <acronym>TARGET</acronym>
  <official_title>Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized controlled clinical trial, investigators will compare the effects on
      [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from
      two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate
      responders (MTX-IRs). Two common RA treatments will be compared: triple therapy
      (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF)
      inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and
      hydroxychloroquine for subjects who were taking this at screening).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting subjects will be screened for eligibility and randomized to a treatment arm.
      Subjects will be randomized to a treatment arm with either synthetic disease-modifying
      antirheumatic drugs (DMARDs) [triple therapy: sulfasalazine, methotrexate, and
      hydroxychloroquine] or biologic DMARDs [etanercept or adalimumab, plus background
      methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at
      screening].

      Once randomized, a baseline visit will be conducted with each subject. Baseline data
      collection includes questionnaires, disease activity score, and the first FDG-PET/CT imaging.
      After the baseline at week 0, subjects will visit with their rheumatologist at weeks 6, 12,
      18, and 24 for safety labs and further collection of disease activity scores and
      questionnaires. The second FDG-PET/CT will be performed at week 24. Blood specimens will be
      collected at weeks 0, 6, 18, and 24 for bioassays. Subject participation will end after the
      week 24 visit.

      Patients and care providers will be unblinded. The FDG-PET/CT image readers will be blinded
      to treatment arm as well as timepoint of image acquisition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Vascular Inflammation as measured by FDG-PET/CT at 6 months</measure>
    <time_frame>0, 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>1 gm bid</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <other_name>Azulfidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200 mg twice daily, not to exceed 6.5mg/kg</description>
    <arm_group_label>Triple therapy (MTX+SSZ+HCQ)</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg SC weekly</description>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>40 mg SQ every other week</description>
    <arm_group_label>TNF inhibitor (etanercept or adalimumab)</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill American College of Rheumatology/European League Against Rheumatism 2010
             criteria for RA

          -  Men ≥ 45 years and women ≥ 50 years

          -  MTX monotherapy for ≥ 8 weeks at ≥ 15mg weekly or ≥ 7.5 mg weekly with a documented
             intolerance to higher doses

          -  No non-biologic DMARDs in preceding two months (other than MTX and HCQ)

          -  Disease Activity Score-28 &gt; 3.2

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Use of biologic DMARD within the past 6 months or use of rituximab ever

          -  Current use of &gt;10mg per day of prednisone

          -  Use of a moderate- or high-intensity statin lipid lowering drug or PCSK9 inhibitor in
             the past 12 months

          -  Prior patient reported, physician diagnosed clinical cardiovascular (CV) event

          -  Insulin-dependent or uncontrolled diabetes mellitus (DM)

          -  Systemic lupus erythematosus (SLE) or other autoimmune and chronic inflammatory
             diseases (i.e. inflammatory bowel disease, sarcoidosis)

          -  Cancer treated in the last 5 years (except basal and squamous cell) or any lymphoma or
             melanoma

          -  Known pregnancy, HIV, Hepatitis B Virus, Hepatitis C Virus, active (or untreated
             latent) tuberculosis

          -  Baseline: liver, renal or blood count abnormalities, Glucose-6-phosphate dehydrogenase
             (G6PD) deficiency

          -  Known sulfa allergy, macular disease or hypersensitivity to treatments; known
             demyelinating disease; uncompensated Congestive Heart Failure (CHF)

          -  Intra-articular injection within the 4 weeks prior to baseline FDG PET/CT

          -  2 or more high dose radiation scans in the past year (CT scan with contrast,
             angiogram, SPECT nuclear medicine scan, myocardial/cardiac perfusion scan)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Solomon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel H Solomon</last_name>
    <email>dsolomon@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Bathon</last_name>
    <email>jmb2311@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laticia Woodruff, RN</last_name>
      <phone>205-934-9843</phone>
      <email>lplove@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeraldine Guzman</last_name>
      <email>JBGuzman@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Charles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigid Freyne, MD Inc.</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigid Freyne, MD</last_name>
      <phone>951-696-4600</phone>
      <email>Brigid.Freyne@BrigidFreyne.com</email>
    </contact>
    <investigator>
      <last_name>Brigid Freyne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Krueger</last_name>
      <email>melissa.krueger@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Graf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert W. Levin, MD, PA</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Androsiglio</last_name>
      <phone>727-734-6631</phone>
      <email>crclori@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Robert W Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Florida Clinical Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Athime</last_name>
      <phone>813-879-1188</phone>
      <phone_ext>103</phone_ext>
      <email>kathime@ymail.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Carns</last_name>
      <phone>312-503-1137</phone>
      <email>m-carns@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Ruderman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Richeson</last_name>
      <phone>859-323-2093</phone>
      <email>dianne.richeson@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Kristine M Lohr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Lormore</last_name>
      <phone>301-942-6610</phone>
      <email>MLORMORE@arapc.com</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Bass Goldman</last_name>
      <phone>301-942-6610</phone>
      <email>TBGoldman@arapc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alan K Matsumoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Brownmiller</last_name>
      <phone>617-643-5691</phone>
      <email>SethBrownmiller@partners.org</email>
    </contact>
    <investigator>
      <last_name>Marcy Bolster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengxin Lu</last_name>
      <phone>617-525-8786</phone>
      <email>FLu1@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Elena Massarotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Sarazin</last_name>
      <phone>734-998-1271</phone>
      <email>jsarazin@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elena Schiopu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ritter, RN</last_name>
      <phone>314-362-7306</phone>
      <email>michelle.ritter@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Parks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Brooker, RN</last_name>
      <phone>603-650-4717</phone>
      <email>Jill.B.Brooker@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Switzer</last_name>
      <phone>603-650-8587</phone>
      <email>Ashley.E.Ladd@hitchcock.org</email>
    </contact_backup>
    <investigator>
      <last_name>William FC Rigby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Rheumatology, LLP</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Kessler</last_name>
      <phone>518-533-1325</phone>
      <email>kkessler@joint-docs.com</email>
    </contact>
    <investigator>
      <last_name>Joel Kremer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cidney Schultz</last_name>
      <phone>718-918-6212</phone>
      <email>Cidney.Schultz@nbhn.net</email>
    </contact>
    <investigator>
      <last_name>Barbara Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aret Ozkan</last_name>
      <phone>718-270-1190</phone>
      <email>Aret.Ozkan@downstate.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Ginzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keriann Leppla</last_name>
      <phone>516-708-2674</phone>
      <email>kleppla@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Diane Horowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luz Alvarado</last_name>
      <phone>646-577-3555</phone>
      <email>Luz.Alvarado@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Rhina Medina</last_name>
      <phone>347-596-0736</phone>
      <email>Rhina.Medina@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Scher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai- Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garnette Mason, MPH</last_name>
      <phone>212-241-4824</phone>
      <email>garnette.mason@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Yousaf Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Broderick</last_name>
      <phone>212-342-2713</phone>
      <email>rb3173@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Saxena Beem</last_name>
      <phone>919-966-0545</phone>
      <email>ssaxena@email.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Norfleet Walker</last_name>
      <phone>919-843-6619</phone>
      <email>jann1@email.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rumey Ishizawar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kisela</last_name>
      <phone>216-444-4887</phone>
      <email>KiselaE@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Elaine Husni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Jin</last_name>
      <phone>503-494-5571</phone>
      <email>jinm@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Cong-Qui Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Research Center</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Claycomb</last_name>
      <phone>814-296-6101</phone>
      <email>altoonaresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Marc</last_name>
      <phone>215-662-6335</phone>
      <email>adam.marc@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Hope, RN</last_name>
      <phone>412-647-2638</phone>
      <email>hopelk@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Moreland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Diekman</last_name>
      <phone>713-500-6852</phone>
      <email>Laura.Diekman@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Beth Scholtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Fessel</last_name>
      <phone>206-386-2007</phone>
      <email>melissa@seattlera.com</email>
    </contact>
    <investigator>
      <last_name>Philip Mease, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.targetra.org</url>
    <description>Study Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Daniel H. Solomon, M.D.,MPH</investigator_full_name>
    <investigator_title>Chief, Section of Clinical Sciences</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

